• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eaton Vance Ohio Municipal Income Trust (NQ:EVO)

    2.646 -0.044 (-1.65%)
    Streaming Delayed Price Updated: 12:14 PM EDT, Apr 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Eaton Vance Ohio Municipal Income Trust

    < Previous 1 2 3 4 5 Next >
    News headline image
    Evotec Nominates Dieter Weinand as Supervisory Board Chairman
    Via ACCESS Newswire
    News headline image
    Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
    Via ACCESS Newswire
    News headline image
    Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
    Via ACCESS Newswire
    News headline image
    Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
    Via ACCESS Newswire
    News headline image
    Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
    Via ACCESS Newswire
    News headline image
    Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
    Via ACCESS Newswire
    News headline image
    Evotec Announces Change in Management Board
    Via ACCESS Newswire
    News headline image
    Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
    Via ACCESS Newswire
    News headline image
    Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
    Via ACCESS Newswire
    News headline image
    Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
    Via ACCESS Newswire
    News headline image
    Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
    Via ACCESS Newswire
    News headline image
    Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
    Via ACCESS Newswire
    News headline image
    Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
    Via ACCESS Newswire
    News headline image
    In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
    Via ACCESS Newswire
    News headline image
    Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
    Via ACCESS Newswire
    News headline image
    Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
    Via ACCESS Newswire
    News headline image
    Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
    Via ACCESS Newswire
    News headline image
    Evotec SE to announce first half-year results 2025 on 13 August 2025
    Via ACCESS Newswire
    News headline image
    Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
    Via ACCESS Newswire
    News headline image
    Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
    Via ACCESS Newswire
    News headline image
    Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
    Via ACCESS Newswire
    News headline image
    Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
    Via ACCESS Newswire
    News headline image
    Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
    Via ACCESS Newswire
    News headline image
    Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
    Via ACCESS Newswire
    News headline image
    Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
    Via ACCESS Newswire
    News headline image
    Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
    Via ACCESS Newswire
    News headline image
    Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
    Via ACCESS Newswire
    News headline image
    Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
    Via ACCESS Newswire
    News headline image
    Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
    Via ACCESS Newswire
    News headline image
    Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
    Via ACCESS Newswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.